Skip to main content
. 2010 Mar 26;2:83–96. doi: 10.2147/cmar.s7540

Figure 4.

Figure 4

Treatment schema and results in phase 3 randomized trials utilizing interferon alpha (IFN-α) with/without bevacizumab. Results of the two studies AVOREN and CALGB 90206 are illustrated, demonstrating overall response rates (ORR), median progression-free survival (PFS), and median overall survival (OS).

aRini et al;6 bEscudier et al;5 cRini et al,44 P = 0.069 (stratified log rank); dEscudier et al,45 P = 0.069 (stratified log rank).